Glimerit-MP 1 Tablet ER is a combination oral antidiabetic medication containing Glimepiride (1mg), Metformin (500mg), and Pioglitazone (15mg), formulated for extended release to provide sustained glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to enhanced glucose uptake and utilization. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), improving insulin sensitivity in adipose tissue, muscle, and the liver. The combination of these agents targets multiple pathophysiological defects in type 2 diabetes, resulting in improved glycemic control. Glimerit-MP 1 Tablet ER is indicated as an adjunct to diet and exercise to improve glycemic control in adults inadequately controlled on monotherapy or dual therapy. The extended-release formulation allows for once-daily dosing, enhancing patient compliance. Caution is advised in patients with renal or hepatic impairment, heart failure, or risk of lactic acidosis. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during therapy. This combination therapy should be used under medical supervision to optimize therapeutic outcomes and minimize adverse effects.